ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Rating) – Investment analysts at Cantor Fitzgerald issued their FY2022 earnings estimates for ANI Pharmaceuticals in a research note issued to investors on Wednesday, April 27th. Cantor Fitzgerald analyst B. Folkes expects that the specialty pharmaceutical company will post earnings per share of $0.69 for the year. Cantor Fitzgerald has a “Neutral” rating on the stock.
Other research analysts have also issued research reports about the company. Zacks Investment Research raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, March 14th. StockNews.com cut shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday. TheStreet cut shares of ANI Pharmaceuticals from a “c-” rating to a “d+” rating in a research note on Wednesday, March 30th. Finally, Raymond James decreased their price target on shares of ANI Pharmaceuticals from $65.00 to $47.00 and set an “outperform” rating on the stock in a report on Wednesday, March 16th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, ANI Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $56.67.
ANI Pharmaceuticals (NASDAQ:ANIP – Get Rating) last issued its earnings results on Tuesday, March 15th. The specialty pharmaceutical company reported $0.38 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.69 by ($0.31). The business had revenue of $60.93 million for the quarter, compared to the consensus estimate of $58.25 million. ANI Pharmaceuticals had a negative net margin of 19.71% and a positive return on equity of 14.10%. During the same period in the previous year, the firm earned $0.65 EPS.
Several institutional investors have recently made changes to their positions in the company. Meeder Asset Management Inc. grew its holdings in shares of ANI Pharmaceuticals by 5,952.2% during the 3rd quarter. Meeder Asset Management Inc. now owns 1,392 shares of the specialty pharmaceutical company’s stock valued at $45,000 after purchasing an additional 1,369 shares during the last quarter. Metropolitan Life Insurance Co NY purchased a new position in shares of ANI Pharmaceuticals in the third quarter worth about $95,000. Oregon Public Employees Retirement Fund lifted its stake in shares of ANI Pharmaceuticals by 30.8% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 4,778 shares of the specialty pharmaceutical company’s stock valued at $134,000 after acquiring an additional 1,126 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in ANI Pharmaceuticals during the 4th quarter valued at about $196,000. Finally, Louisiana State Employees Retirement System grew its position in ANI Pharmaceuticals by 19.2% during the 1st quarter. Louisiana State Employees Retirement System now owns 6,200 shares of the specialty pharmaceutical company’s stock worth $203,000 after acquiring an additional 1,000 shares during the last quarter. 53.51% of the stock is owned by institutional investors.
In other news, CEO Nikhil Lalwani bought 7,224 shares of the company’s stock in a transaction that occurred on Monday, March 21st. The stock was bought at an average price of $27.69 per share, for a total transaction of $200,032.56. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Muthusamy Shanmugam bought 5,000 shares of the business’s stock in a transaction on Thursday, March 17th. The stock was purchased at an average cost of $27.65 per share, with a total value of $138,250.00. The disclosure for this purchase can be found here. Insiders bought a total of 17,224 shares of company stock worth $477,083 in the last three months. Insiders own 27.20% of the company’s stock.
ANI Pharmaceuticals Company Profile (Get Rating)
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies.
- Get a free copy of the StockNews.com research report on ANI Pharmaceuticals (ANIP)
- Rogers Communication Stock Should Be Launching Higher
- O’Reilly Automotive Hits A Pothole
- Iridium Communications Stock is Ready to Return to Orbit
- There’s An Institutional Floor In Keurig Dr. Pepper
- Ford Falls Despite Optimistic Outlook
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.